ValuEngine upgraded shares of Novan (NASDAQ:NOVN) from a strong sell rating to a sell rating in a research note released on Monday, April 2nd.
Shares of NASDAQ:NOVN remained flat at $$3.17 during trading on Monday. The stock had a trading volume of 8,934 shares, compared to its average volume of 83,321. Novan has a 12 month low of $2.65 and a 12 month high of $7.33. The company has a market capitalization of $80.98, a PE ratio of -1.37 and a beta of 1.22. The company has a current ratio of 0.44, a quick ratio of 0.44 and a debt-to-equity ratio of -0.01.
An institutional investor recently raised its position in Novan stock. Vanguard Group Inc. raised its position in shares of Novan (NASDAQ:NOVN) by 7.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 194,611 shares of the company’s stock after acquiring an additional 13,257 shares during the period. Vanguard Group Inc. owned approximately 1.22% of Novan worth $785,000 at the end of the most recent quarter. Institutional investors and hedge funds own 3.20% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.thelincolnianonline.com/2018/04/19/novan-novn-stock-rating-upgraded-by-valuengine.html.
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Novan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan and related companies with MarketBeat.com's FREE daily email newsletter.